The availability of new antifungal agents with novel mechanisms of action has stimulated
renewed interest in combination antifungal therapies. In particular, and despite the limited …

The persistence of high morbidity and mortality from systemic fungal infections despite the
availability of novel antifungals points to the need for effective treatment strategies …

Invasive fungal infections remain a major cause of morbidity and mortality in
immunocompromised patients, and such infections are a substantial burden to healthcare …

Combination antifungal therapy has been an area of research and clinical interest since
systemic antifungals became available decades ago. In vitro and clinical data were …

Fungal infections represent an increasing threat to a growing number of immune-and
medically compromised patients. Fungi are eukaryotic organisms and, as such, there is a …

As invasive fungal infections in immunocompromised patients become increasingly
important, the field of antifungal chemotherapy continues to evolve rapidly. New agents have …

The introduction of new antifungal agents (eg, echinocandins, second-generation triazoles)
in the past decade has transformed the management of invasive mycoses to the point that …

Concurrent or sequential antifungal treatment for invasive mycoses has been typically
considered as an option to improve results of monotherapy. However, data on the efficacy of …

Invasive fungal infections have emerged as important causes of morbidity and mortality in
immunocompromised patients. In response to this challenge, the field of antifungal …

Invasive fungal infections are an important cause of human mortality and morbidity,
particularly for immunocompromised populations. However, there remains a paucity of …